-
Something wrong with this record ?
Chemobrain in blood cancers: How chemotherapeutics interfere with the brain's structure and functionality, immune system, and metabolic functions
M. Skurlova, K. Holubova, L. Kleteckova, T. Kozak, H. Kubova, J. Horacek, K. Vales
Language English Country United States
Document type Journal Article, Review
Grant support
AZV 16-29857A
Ministry of Health of the Czech Republic
LO1611
MEYS
PubMed
37265248
DOI
10.1002/med.21977
Knihovny.cz E-resources
- MeSH
- Hematologic Neoplasms * metabolism pathology MeSH
- Immune System MeSH
- Chemotherapy-Related Cognitive Impairment * metabolism pathology MeSH
- Humans MeSH
- Brain metabolism MeSH
- Neoplasms * drug therapy MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Cancer treatment brings about a phenomenon not fully clarified yet, termed chemobrain. Its strong negative impact on patients' well-being makes it a trending topic in current research, interconnecting many disciplines from clinical oncology to neuroscience. Clinical and animal studies have often reported elevated concentrations of proinflammatory cytokines in various types of blood cancers. This inflammatory burst could be the background for chemotherapy-induced cognitive deficit in patients with blood cancers. Cancer environment is a dynamic interacting system. The review puts into close relationship the inflammatory dysbalance and oxidative/nitrosative stress with disruption of the blood-brain barrier (BBB). The BBB breakdown leads to neuroinflammation, followed by neurotoxicity and neurodegeneration. High levels of intracellular reactive oxygen species (ROS) induce the progression of cancer resulting in increased mutagenesis, conversion of protooncogenes to oncogenes, and inactivation of tumor suppression genes to trigger cancer cell growth. These cell alterations may change brain functionality, as well as morphology. Multidrug chemotherapy is not without consequences to healthy tissue and could even be toxic. Specific treatment impacts brain function and morphology, functions of the immune system, and metabolism in a unique mixture. In general, a chemo-drug's effects on cognition in cancer are not direct and/or in-direct, usually a combination of effects is more probable. Last but not least, chemotherapy strongly impacts the immune system and could contribute to BBB disruption. This review points out inflammation as a possible mechanism of brain damage during blood cancers and discusses chemotherapy-induced cognitive impairment.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000164
- 003
- CZ-PrNML
- 005
- 20240213093008.0
- 007
- ta
- 008
- 240109s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/med.21977 $2 doi
- 035 __
- $a (PubMed)37265248
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Skurlova, M $u Department of Experimental Psychopharmacology, National Institute of Mental Health, Klecany, Czech Republic
- 245 10
- $a Chemobrain in blood cancers: How chemotherapeutics interfere with the brain's structure and functionality, immune system, and metabolic functions / $c M. Skurlova, K. Holubova, L. Kleteckova, T. Kozak, H. Kubova, J. Horacek, K. Vales
- 520 9_
- $a Cancer treatment brings about a phenomenon not fully clarified yet, termed chemobrain. Its strong negative impact on patients' well-being makes it a trending topic in current research, interconnecting many disciplines from clinical oncology to neuroscience. Clinical and animal studies have often reported elevated concentrations of proinflammatory cytokines in various types of blood cancers. This inflammatory burst could be the background for chemotherapy-induced cognitive deficit in patients with blood cancers. Cancer environment is a dynamic interacting system. The review puts into close relationship the inflammatory dysbalance and oxidative/nitrosative stress with disruption of the blood-brain barrier (BBB). The BBB breakdown leads to neuroinflammation, followed by neurotoxicity and neurodegeneration. High levels of intracellular reactive oxygen species (ROS) induce the progression of cancer resulting in increased mutagenesis, conversion of protooncogenes to oncogenes, and inactivation of tumor suppression genes to trigger cancer cell growth. These cell alterations may change brain functionality, as well as morphology. Multidrug chemotherapy is not without consequences to healthy tissue and could even be toxic. Specific treatment impacts brain function and morphology, functions of the immune system, and metabolism in a unique mixture. In general, a chemo-drug's effects on cognition in cancer are not direct and/or in-direct, usually a combination of effects is more probable. Last but not least, chemotherapy strongly impacts the immune system and could contribute to BBB disruption. This review points out inflammation as a possible mechanism of brain damage during blood cancers and discusses chemotherapy-induced cognitive impairment.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a kognitivní porucha po chemoterapii $x metabolismus $x patologie $7 D000084202
- 650 12
- $a nádory $x farmakoterapie $7 D009369
- 650 12
- $a hematologické nádory $x metabolismus $x patologie $7 D019337
- 650 _2
- $a mozek $x metabolismus $7 D001921
- 650 _2
- $a imunitní systém $7 D007107
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Holubova, K $u Department of Experimental Psychopharmacology, National Institute of Mental Health, Klecany, Czech Republic
- 700 1_
- $a Kleteckova, L $u Department of Experimental Psychopharmacology, National Institute of Mental Health, Klecany, Czech Republic $1 https://orcid.org/0000000274992757
- 700 1_
- $a Kozak, T $u Department of Developmental Epileptology, Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Kubova, H $u Department of Internal Medicine and Hematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Horacek, J $u Department of Experimental Psychopharmacology, National Institute of Mental Health, Klecany, Czech Republic
- 700 1_
- $a Vales, K $u Department of Experimental Psychopharmacology, National Institute of Mental Health, Klecany, Czech Republic
- 773 0_
- $w MED00003265 $t Medicinal research reviews $x 1098-1128 $g Roč. 44, č. 1 (2024), s. 5-22
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37265248 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093006 $b ABA008
- 999 __
- $a ok $b bmc $g 2049072 $s 1209858
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 44 $c 1 $d 5-22 $e 20230602 $i 1098-1128 $m Medicinal research reviews $n Med Res Rev $x MED00003265
- GRA __
- $a AZV 16-29857A $p Ministry of Health of the Czech Republic
- GRA __
- $a LO1611 $p MEYS
- LZP __
- $a Pubmed-20240109